BACKGROUND: Everyday life demands continuous flexibility in thought and behavior. We examined whether individual differences in dopamine function are related to variability in the effects of amphetamine on one aspect of flexibility: task switching. METHODS: Forty healthy human participants performed a task-switching paradigm following placebo and oral amphetamine administration. [(18)F]fallypride was used to measure D2/D3 baseline receptor availability and amphetamine-stimulated dopamine release. RESULTS: The majority of the participants showed amphetamine-induced benefits through reductions in switch costs. However, such benefits were variable. Individuals with higher baseline thalamic and cortical receptor availability and striatal dopamine release showed greater reductions in switch costs following amphetamine than individuals with lower levels. The relationship between dopamine receptors and stimulant-enhanced flexibility was partially mediated by striatal dopamine release. CONCLUSIONS: These data indicate that the impact of the psychostimulant on cognitive flexibility is influenced by the status of dopamine within a thalamocorticostriatal network. Beyond demonstrating a link between this dopaminergic network and the enhancement in task switching, these neural measures accounted for unique variance in predicting the psychostimulant-induced cognitive enhancement. These results suggest that there may be measurable aspects of variability in the dopamine system that predispose certain individuals to benefit from and hence use psychostimulants for cognitive enhancement.
BACKGROUND: Everyday life demands continuous flexibility in thought and behavior. We examined whether individual differences in dopamine function are related to variability in the effects of amphetamine on one aspect of flexibility: task switching. METHODS: Forty healthy humanparticipants performed a task-switching paradigm following placebo and oral amphetamine administration. [(18)F]fallypride was used to measure D2/D3 baseline receptor availability and amphetamine-stimulated dopamine release. RESULTS: The majority of the participants showed amphetamine-induced benefits through reductions in switch costs. However, such benefits were variable. Individuals with higher baseline thalamic and cortical receptor availability and striatal dopamine release showed greater reductions in switch costs following amphetamine than individuals with lower levels. The relationship between dopamine receptors and stimulant-enhanced flexibility was partially mediated by striatal dopamine release. CONCLUSIONS: These data indicate that the impact of the psychostimulant on cognitive flexibility is influenced by the status of dopamine within a thalamocorticostriatal network. Beyond demonstrating a link between this dopaminergic network and the enhancement in task switching, these neural measures accounted for unique variance in predicting the psychostimulant-induced cognitive enhancement. These results suggest that there may be measurable aspects of variability in the dopamine system that predispose certain individuals to benefit from and hence use psychostimulants for cognitive enhancement.
Authors: Michael Esterman; Yu-Chin Chiu; Benjamin J Tamber-Rosenau; Steven Yantis Journal: Proc Natl Acad Sci U S A Date: 2009-10-05 Impact factor: 11.205
Authors: Venkata S Mattay; Terry E Goldberg; Francesco Fera; Ahmad R Hariri; Alessandro Tessitore; Michael F Egan; Bhaskar Kolachana; Joseph H Callicott; Daniel R Weinberger Journal: Proc Natl Acad Sci U S A Date: 2003-04-25 Impact factor: 11.205
Authors: Douglas D Garrett; Irene E Nagel; Claudia Preuschhof; Agnieszka Z Burzynska; Janina Marchner; Steffen Wiegert; Gerhard J Jungehülsing; Lars Nyberg; Arno Villringer; Shu-Chen Li; Hauke R Heekeren; Lars Bäckman; Ulman Lindenberger Journal: Proc Natl Acad Sci U S A Date: 2015-06-01 Impact factor: 11.205
Authors: Anne S Berry; Vyoma D Shah; Suzanne L Baker; Jacob W Vogel; James P O'Neil; Mustafa Janabi; Henry D Schwimmer; Shawn M Marks; William J Jagust Journal: J Neurosci Date: 2016-11-02 Impact factor: 6.167
Authors: Christopher T Smith; Linh C Dang; Leah L Burgess; Scott F Perkins; M Danica San Juan; Darcy K Smith; Ronald L Cowan; Nam T Le; Robert M Kessler; Gregory R Samanez-Larkin; David H Zald Journal: Psychopharmacology (Berl) Date: 2018-10-22 Impact factor: 4.530
Authors: Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir Journal: Exp Clin Psychopharmacol Date: 2016-08 Impact factor: 3.157
Authors: Christopher T Smith; Jessica Weafer; Ronald L Cowan; Robert M Kessler; Abraham A Palmer; Harriet de Wit; David H Zald Journal: J Psychopharmacol Date: 2016-02-15 Impact factor: 4.153
Authors: Samuel R Chamberlain; Hanneke E M den Ouden; Vanessa Scholz; Roxanne W Hook; Mojtaba Rostami Kandroodi; Johannes Algermissen; Konstantinos Ioannidis; David Christmas; Stephanie Valle; Trevor W Robbins; Jon E Grant Journal: Neuropsychopharmacology Date: 2022-03-08 Impact factor: 8.294